JPRN-UMIN000007913已完成未知
HLA-mismatched allogeneic hematopoietic stem cell transplantation for advanced hematological malignancy using low-dose alemtuzumab - HLA-mismatched HSCT using low-dose alemtuzumab
Division of Hematology, Saitama Medical Center, Jichi Medical University0 个研究点目标入组 14 人开始时间: 2012年6月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 14
研究概览
简要总结
The primary outcome measure was the survival rate with the engraftment of donor cells and without grade III-IV acute graft-vs-host disease (GVHD) at 60 days after transplantation.The primary outcome measure was achieved in 86% of the patients.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 16years-old 至 65years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Exclusion criteria 1.Patients with poorly controlled active infection. 2.Patients with coexistence of malignancy. 3.Patients who are pregnant or nursing. 4.Patients with serious mental disorder. 5.Patients with HIV antibody positive. 6.Patients who are allergic to drugs used in conditioning regimen or GVHD prophylaxis.
研究者
相似试验
已完成
不适用
HLA-mismatched allogeneic hematopoietic stem cell transplantation for high-risk advanced hematological disease with the adjustments of immunosuppressants and low-dose alemtuzumab.High-risk advanced hematological disease(leukemia and malignant lymphoma in non-remission, MDS with more than 20% of blast, and relapsed disease after allogeneic transplantation)JPRN-UMIN000018298Division of Hematology, Saitama Medical Center, Jichi Medical University27
已完成
1 期
HLA-mismatched HSCT for high-risk hematological disease with adjusted immunosuppressabts and low-dose alemtuzumabJPRN-jRCTs031180237Kanda Yoshinobu27
已完成
不适用
Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome Low RiskMDSNCT02757989Groupe Francophone des Myelodysplasies79
尚未招募
1 期
Safety and Efficacy of Gene Therapy of FHL Type 3 Caused by Mutations in the Human UNC13D Gene by Transplantation of a Single Dose of Autologous CD34+ Cells Transduced ex Vivo With the UNC13D LV Vector Expressing the UNC13D cDNAFamilial Hemophagocytic Lymphohistiocytosis Type 3 (FHL 3)NCT06736080Assistance Publique - Hôpitaux de Paris5
尚未招募
2 期
Allogeneic hematopoietic stem cell transplantation from a two HLA-haplotype-mismatched family donor for post-transplant relapse/rejection: A prospective phase II study with statistical validation for survival benefithematologic malignancies relapsing or with rejection after allogeneic hematopoietic stem cell transplantationJPRN-UMIN000043973Hyogo College of Medicine50